Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial.

Giovanni TargherGianluigi LunardiAlessandro MantovaniJennifer MeessenStefano BonapacePier Luigi TemporelliEnrico NicolisDeborah NovelliAntonio ContiLuigi TavazziAldo Pietro MaggioniRoberto Latini

Published in: ESC heart failure (2020)

Higher levels of specific plasma ceramides [especially when used in ratios with Cer(d18:1/24:0)] are associated with increased cardiovascular mortality in ambulatory patients with chronic HF. However, these associations are weakened after adjustment for established cardiovascular risk factors, medication use, and plasma NT-proBNP concentrations.

Keyphrases

cardiovascular risk factors
cardiovascular disease
metabolic syndrome
clinical trial
cardiovascular events
randomized controlled trial
risk factors
heart failure
coronary artery disease
phase iii
phase ii